Annals of Surgical Oncology

, Volume 20, Supplement 3, pp 301–311 | Cite as

Hypermethylation of HIC1 Promoter and Aberrant Expression of HIC1/SIRT1 Might Contribute to the Carcinogenesis of Pancreatic Cancer

  • Gang Zhao
  • Qi Qin
  • Jungang Zhang
  • Yang Liu
  • Shichang Deng
  • Lin Liu
  • Bo Wang
  • Kui Tian
  • Chunyou Wang
Translational Research and Biomarkers



DNA hypermethylation is proved to be involved in carcinogenesis. Because chronic pancreatitis (CP) is a consistent risk factor for pancreatic cancer, the possible alteration and tumor contribute effects of hypermethylated in cancer-1 (HIC1) promoter methylation in CP was investigated.


Methylation of HIC1 promoter HIC1 and SIRT1 expression were detected in human normal pancreas (NP), CP and pancreatic adenocarcinoma tissues. Furthermore, HIC1/SIRT1 pathway was regulated by demethylating reagent and exogenous expression in PANC-1, BxPC-3 and AsPC-1 cell lines, cell biology behavior including proliferation, apoptosis, cell cycle and senescence were detected.


The methylation of HIC1 promoter was demonstrated in 70.3 % pancreatic carcinoma (45 of 64), 47.5 % CP (19 of 40) and 11.4 % NP tissues (4 of 35). Moreover, hypermethylation of HIC1 promoter and deregulation of HIC1 expression in pancreatic cancer were significantly related to high-stage tumor and older patient age. HIC1 promoter hypermethylation was also observed in pancreatic cancer cell lines including PANC-1, BxPC-3 and AsPC-1. Restoration of HIC1 function with 5-aza-dC treatment or pCDNA3FlagHIC1 plasmid transfection leaded to a reduction in cell proliferation, obvious cell senescence, cell cycle arrest and apoptosis, accompanied with acetylated p53 and p21WAF1 of Cip1 upregulation. While after further transfected with pCDNA3FlagSIRT1 plasmid, the growth inhibition, senescence and cycle arrest without apoptosis were partially rescued with deregulated acetylated p53 and p21WAF1 of Cip1.


Our results indicate that hypermethylation of HIC1 promoter in CP may contribute to the aberrant expression of HIC1/SIRT1 pathway and then involve in the pancreatic carcinogenesis.


Pancreatic Cancer Chronic Pancreatitis Pancreatic Cancer Cell Pancreatic Cancer Cell Line Normal Pancreas 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a grant from the National Natural Science Foundation of China (grants 30600594 and 30972900) and the Fundamental Research Funds for the Central Universities of China (grant 2011JC046).

Conflict of interest

All authors have no competing interest to declare.

Supplementary material

10434_2012_2364_MOESM1_ESM.jpg (489 kb)
Supplementary material 1 (JPEG 489 kb)


  1. 1.
    Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Whitcomb DC, Pogue-Geile K. Pancreatitis as a risk for pancreatic cancer. Gastroenterol Clin North Am. 2002;31:663–78.CrossRefGoogle Scholar
  3. 3.
    Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–69.PubMedCrossRefGoogle Scholar
  4. 4.
    Whitcomb DC. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2004;287:G315–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res. 2005;15:72–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 2008;68:10280–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kanai Y, Ushijima S, Ochiai A, Eguchi K, Hui A, Hirohashi S. DNA hypermethylation at the D17S5 locus is associated with gastric carcinogenesis. Cancer Lett. 1998;122:135–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Rathi A, Virmani AK, Harada K, Timmons CF, Miyajima K, Hay RJ, et al. Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Clin Cancer Res. 2003;9:3674–8.PubMedGoogle Scholar
  9. 9.
    Briggs KJ, Corcoran-Schwartz IM, Zhang W, Harcke T, Devereux WL, Baylin SB, et al. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev. 2008;22:770–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Britschgi C, Jenal M, Rizzi M, Mueller BU, Torbett BE, Andres AC, et al. HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br J Haematol. 2008;141:179–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhang W, Zeng X, Briggs KJ, Beaty R, Simons B, Chiu YRW, et al. A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene. 2010;29:2467–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Chen WY, Zeng X, Carter MG, Morrell CN, Chiu YRW, Esteller M, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet. 2003;33:197–202.PubMedCrossRefGoogle Scholar
  13. 13.
    Kanai Y, Hui AM, Sun L, Ushijima S, Sakamoto M, Tsuda H, et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology. 1999;29:703–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Stunkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto-Tellez M, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2007;2:1360–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang Q, Wang SY, Fleuriel C, Leprince D, Rocheleau JV, Piston DW, et al. Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. Proc Natl Acad Sci USA. 2007;104:829–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123:437–48.PubMedCrossRefGoogle Scholar
  17. 17.
    Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia. 2009;11:763–70.PubMedGoogle Scholar
  18. 18.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer-Verlag. 2010.Google Scholar
  19. 19.
    Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T, et al. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res. 1999;5:1147–53.PubMedGoogle Scholar
  20. 20.
    Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol. 2009;3:425–38.PubMedCrossRefGoogle Scholar
  21. 21.
    Fleuriel C, Touka M, Boulay G, Guerardel C, Rood BR, Leprince D. HIC1 (hypermethylated in cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol. 2009;41:26–33.PubMedCrossRefGoogle Scholar
  22. 22.
    Wahab AH, El-Mezayen HA, Sharad H, Rahman SA. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. Tumour Biol. 2011;32:845–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Valenta T, Lukas J, Doubravska L, Fafilek B, Korinek V. HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J. 2006;25:2326–37.PubMedCrossRefGoogle Scholar
  24. 24.
    Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67:6612–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19:1751–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen’s disease. Arch Dermatol Res. 2007;299:103–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Zhao G, Cui J, Zhang JG, Qin Q, Chen Q, Yin T, et al. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther. 2011;18:920–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Hemann MT, Narita M. Oncogenes and senescence: breaking down in the fast lane. Genes Dev. 2007;21:1–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol. 2008;20:150–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Bihani T, Mason DX, Jackson TJ, Chen SC, Boettner B, Lin AW. Differential oncogenic Ras signaling and senescence in tumor cells. Cell Cycle. 2004;3:1201–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Kim EJ, Um SJ. SIRT1: roles in aging and cancer. Biochem Mol Biol Rep. 2008;41:751–6.Google Scholar
  32. 32.
    Canto C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab. 2009;20:325–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460:587–91.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Gang Zhao
    • 1
  • Qi Qin
    • 1
  • Jungang Zhang
    • 1
  • Yang Liu
    • 1
  • Shichang Deng
    • 1
  • Lin Liu
    • 1
  • Bo Wang
    • 1
  • Kui Tian
    • 1
  • Chunyou Wang
    • 1
  1. 1.Pancreatic Disease Institute, Union HospitalWuhan CityChina

Personalised recommendations